2-[(5Z)-5-[(2E)-2-methyl-3-phenylprop-2-en-1-ylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid
| Title | Journal |
|---|---|
| Epalrestat Stimulated Oxidative Stress, Inflammation, and Fibrogenesis in Mouse Liver. | Toxicological sciences : an official journal of the Society of Toxicology 20180601 |
| [Protective effect of epalrestat against high glucose-induced endothelial cell injuries]. | Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20120601 |
| Progresses in the pursuit of aldose reductase inhibitors: the structure-based lead optimization step. | European journal of medicinal chemistry 20120501 |
| Antidiabetogenic oligostilbenoids and 3-ethyl-4-phenyl-3,4-dihydroisocoumarins from the bark of Shorea roxburghii. | Bioorganic & medicinal chemistry 20120115 |
| Design, synthesis, and biological evaluation of novel (1-thioxo-1,2,3,4-tetrahydro-β-carbolin-9-yl)acetic acids as selective inhibitors for AKR1B1. | Bioorganic & medicinal chemistry 20120101 |
| 1,2-Benzothiazine 1,1-dioxide carboxylate derivatives as novel potent inhibitors of aldose reductase. | Bioorganic & medicinal chemistry 20111201 |
| AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. | Toxicology and applied pharmacology 20110815 |
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | Journal of medicinal chemistry 20110714 |
| Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling. | Journal of ethnopharmacology 20110107 |
| In vitro evaluation of 5-arylidene-2-thioxo-4-thiazolidinones active as aldose reductase inhibitors. | Bioorganic & medicinal chemistry letters 20110101 |
| 6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2. | Bioorganic & medicinal chemistry letters 20101001 |
| Chromene-3-carboxamide derivatives discovered from virtual screening as potent inhibitors of the tumour maker, AKR1B10. | Bioorganic & medicinal chemistry 20100401 |
| [Research progress in aldose reductase]. | Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20100401 |
| Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine. | Journal of diabetes and its complications 20100101 |
| Aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy: a review. | Journal of diabetes and its complications 20100101 |
| Tau protein and tau aggregation inhibitors. | Neuropharmacology 20100101 |
| Anti-ischaemic activity of an antioxidant aldose reductase inhibitor on diabetic and non-diabetic rat hearts. | The Journal of pharmacy and pharmacology 20100101 |
| Rhodanineacetic acid derivatives as potential drugs: preparation, hydrophobic properties and antifungal activity of (5-arylalkylidene-4-oxo-2-thioxo-1,3-thiazolidin-3-yl)acetic acids. | Molecules (Basel, Switzerland) 20091020 |
| [Examination of questionnaires regarding diabetic peripheral neuropathy in epalrestat-treated patients and their usefulness in the treatment of the patients during the treatment course]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20091001 |
| [Inhibition effect of epalrestat on rat lens osmotic expansion]. | Yao xue xue bao = Acta pharmaceutica Sinica 20091001 |
| Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. | The Journal of biological chemistry 20090925 |
| Docking and molecular dynamics studies toward the binding of new natural phenolic marine inhibitors and aldose reductase. | Journal of molecular graphics & modelling 20090901 |
| [Progress in therapy for and diagnosis of diabetic neuropathies]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20090410 |
| [Pathophysiology and treatment for diabetic neuropathy]. | Rinsho shinkeigaku = Clinical neurology 20090401 |
| Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes. | Endocrine journal 20090101 |
| Inhibitory activities of prenylated flavonoids from Sophora flavescens against aldose reductase and generation of advanced glycation endproducts. | The Journal of pharmacy and pharmacology 20080901 |
| Stratified analyses for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor, epalrestat. | Diabetic medicine : a journal of the British Diabetic Association 20080701 |
| Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. | Arteriosclerosis, thrombosis, and vascular biology 20080601 |
| Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy. | Pharmacotherapy 20080501 |
| Design and synthesis of N-(3,5-difluoro-4-hydroxyphenyl)benzenesulfonamides as aldose reductase inhibitors. | Bioorganic & medicinal chemistry 20080401 |
| Erigeroflavanone, a flavanone derivative from the flowers of Erigeron annuus with protein glycation and aldose reductase inhibitory activity. | Journal of natural products 20080401 |
| Aldose reductase inhibitor ONO-2235 restores the alterations of bladder nerve growth factor and neurotrophin receptor p75 genetic expression in streptozotocin induced diabetic rats. | The Journal of urology 20071101 |
| A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT). | Diabetes research and clinical practice 20070901 |
| Phenolic marine natural products as aldose reductase inhibitors. | Journal of natural products 20061001 |
| Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. | Diabetes care 20060701 |
| Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients. | Journal of the peripheral nervous system : JPNS 20060601 |
| Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics. | Neurology 20060523 |
| Permeability characteristics of novel aldose reductase inhibitors using rat jejunum in vitro. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060501 |
| Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy. | Journal of diabetes and its complications 20060101 |
| The role of sorbitol pathway and treatment effect of aldose reductase inhibitor ONO2235 in the up-regulation of cardiac M2-muscarinic receptors in streptozotocin-induced diabetic rats. | Neuroscience letters 20050701 |
| [Progress on the drug therapy for diabetic microangiopathies: aldose reductase inhibitor]. | Nihon rinsho. Japanese journal of clinical medicine 20050601 |
| [Nerve flow dynamics in the pathogenesis of diabetic neuropathy]. | Nihon rinsho. Japanese journal of clinical medicine 20050601 |
| [Development of therapeutic agents for diabetic neuropathies]. | Nihon rinsho. Japanese journal of clinical medicine 20050601 |
| Influence of the polyol pathway on norepinephrine transporter reduction in diabetic cardiac sympathetic nerves: implications for heterogeneous accumulation of MIBG. | European journal of nuclear medicine and molecular imaging 20050401 |
| Structures and aldose reductase inhibitory effects of bromophenols from the red alga Symphyocladia latiuscula. | Journal of natural products 20050401 |
| Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients. | Hepato-gastroenterology 20050101 |
| Anti-diabetic activities of fucosterol from Pelvetia siliquosa. | Archives of pharmacal research 20041101 |
| Alteration of urinary sorbitol excretion in WBN-kob diabetic rats - treatment with an aldose reductase inhibitor. | The Journal of endocrinology 20040601 |
| Aldose reductase structures: implications for mechanism and inhibition. | Cellular and molecular life sciences : CMLS 20040401 |
| [Effects of angiotensin II receptor blockers, angiotensin converting enzyme inhibitors, 3-hydroxy-3-methyl glutaryl (HMG) CoA reductase inhibitors, amlodipine and epalrestat on cultured basilar artery smooth muscle cell proliferation]. | Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20040301 |
| Effects of an aldose reductase inhibitor on gastroenteropathy in streptozotocin-diabetic rats. | Diabetes research and clinical practice 20031101 |
| Effects of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy and gastroparesis. | Internal medicine (Tokyo, Japan) 20030801 |
| [Improved method of epalrestat synthesis]. | Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20030801 |
| Substituted pyrrol-1-ylacetic acids that combine aldose reductase enzyme inhibitory activity and ability to prevent the nonenzymatic irreversible modification of proteins from monosaccharides. | Journal of medicinal chemistry 20030130 |
| Polyol pathway and protein kinase C activity of rat Schwannoma cells. | Diabetes/metabolism research and reviews 20030101 |
| Effects of eparlestat on plasma levels of advanced glycation end products in patients with type 2 diabetes. | In vivo (Athens, Greece) 20030101 |
| Urinary sorbitol measurement and the effect of an aldose reductase inhibitor on its concentration in the diabetic state. | Journal of diabetes and its complications 20030101 |
| [Prevention and treatment of diabetic neuropathy]. | Nihon rinsho. Japanese journal of clinical medicine 20021001 |
| Improvement of corneal fluorescein staining in post cataract surgery of diabetic patients by an oral aldose reductase inhibitor, ONO-2235. | The British journal of ophthalmology 20020801 |
| New flavonol oligoglycosides and polyacylated sucroses with inhibitory effects on aldose reductase and platelet aggregation from the flowers of Prunus mume. | Journal of natural products 20020801 |
| Role of sorbitol in the up-regulation of urinary bladder M(2) muscarinic receptors in streptozotocin-induced diabetic rats. | Neurourology and urodynamics 20020101 |
| Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients. | Journal of diabetes and its complications 20020101 |
| Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules. | Journal of diabetes and its complications 20020101 |
| Effects of renal sorbitol accumulation on urinary excretion of enzymes in hyperglycaemic rats. | Annals of clinical biochemistry 20010701 |
| Abnormal axonal inward rectifier in streptozocin-induced experimental diabetic neuropathy. | Brain : a journal of neurology 20010601 |
| Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. | Diabetes care 20010601 |
| Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes. | Pharmacology 20010501 |
| Glucose-induced hyperproliferation of cultured rat aortic smooth muscle cells through polyol pathway hyperactivity. | Diabetologia 20010401 |
| Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. | Life sciences 20010105 |
| Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. | Journal of diabetes and its complications 20010101 |
| Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor. | Experimental neurology 19980601 |
| Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. | Journal of medicinal chemistry 19850701 |